Research Article

Identification of a Prognostic Model Based on Immune Cell Signatures in Clear Cell Renal Cell Carcinoma

Xuezhong Shi, Yali Niu, Yongli Yang, Nana Wang, Mengyang Yuan, Chaojun Yang, Ani Dong, Huili Zhu, and Xiaocan Jia

Department of Epidemiology and Biostatistics, College of Public Health, Zhengzhou University, Zhengzhou, 450001 Henan, China

Correspondence should be addressed to Xiaocan Jia; jxc@zzu.edu.cn

Received 24 June 2022; Revised 22 July 2022; Accepted 30 July 2022; Published 23 August 2022

1. Introduction

Clear cell renal cell carcinoma (ccRCC) was a cancer with an incidence of 2.2% and a lethality of 1.8% annually according to Global Cancer Observatory reported in 2020 [1]. About 20-30% of ccRCC patients has metastasized at the time of diagnosis, with 5-year survival rates of less than 10% and weak sensitivity to radiotherapy and chemotherapy [2, 3]. Given that, it was significant to screen novel biomarkers with higher predictive value for the ccRCC patients.

The tumor microenvironment (TME) was a complex dynamic multicellular ecosystem consisting of a mixture of immune cells, stromal cells, cancer cells, and other components [4, 5]. Immune cells in the TME were long identified as a pivotal and central area of oncology investigation, performing an invaluable role in the prognosis, immune escape, and treatment resistance of malignancies [6, 7]. Dai et al. [8] postulated that intratumor CXCL13+ CD8+ T cell infiltration compromised the function of CD8+ T cells, rendering ccRCC patients with poor clinical outcome. Jonasch et al. [9] uncovered that the interaction of genomic instability with the TME could modulate the immune cell populations of ccRCC and affected the survival of ccRCC patients, providing innovative insights for targeted therapy.

However, the majority of present studies evaluating the effect of immune cells on ccRCC were centered on minority immune cells or model construction based on immune-related genes. Wu et al. [10] identified two CD8+ T cell-associated molecular clusters in ccRCC to provide guidance for prognosis prediction and immunotherapy. Peng et al. [11] constructed a TME-related genes model with prognostic value using immune or stromal scores after ESTIMATE algorithm to
predict patients’ survival outcomes and immunotherapy responses. In addition, Gu et al. [12] developed an immune risk score model to assess the prognosis of ccRCC patients by the CIBERSORT algorithm. The CIBERSORT algorithm only counted 22 immune cells, and most immune cell signatures (ICS) were not included [13]. Consequently, there was an urgent demand to adopt a new assessment system including more ICS to predict ccRCC prognosis and guide therapy.

In this study, we utilized The Cancer Genome Atlas (TCGA) - kidney renal clear cell carcinoma (KIRC) cohort to construct an ICS score model based on 184 ICS and validated in E-MTAB-1980 cohort. Moreover, the relationships between the model and immune landscape, genetic mutations, and ailment treatment were further elaborated. This study envisaged mining prognostic indicators to assist oncologists in identifying personalized treatment strategies.

2. Methods

2.1. Data Collection and Processing. Figure 1 displays the flowchart of our study process. KIRC (539 tumor samples) was retrieved from TCGA database (https://portal.gdc.cancer.gov/) as training cohort. E-MTAB-1980 (101 tumor samples) was downloaded from ArrayExpress database (https://www.ebi.ac.uk/arrayexpress/) as external validation cohort. Patients were ruled out if they were not a tumor sample or did not have a complete record of clinical information (survival time, survival status, age, stage, grade, and gender) in TCGA database. The batch effect between the two cohorts was corrected using the “sva” package. For normalization, transcripts per million values were processed by log2 (value + 1), which were analogous to gene expression from microarrays and comparable between patients.

2.2. Gene Set Enrichment Analysis. A total of 184 ICS were obtained by retrieving previous literature [14]. The single-sample gene set enrichment analysis (ssGSEA) [15] was implemented to calculate the normalized enrichment score (NES) of each ICS using the “GSVA” package. The NES was considered as the infiltration levels of 184 ICS for each ccRCC patient.

2.3. Construction of ICS Score Model. Univariate Cox regression was performed to screen the prognosis-related signatures in the training cohort. In addition, the Least absolute shrinkage and selection operator (Lasso)-Cox regression was applied to exclude variables with a regression coefficient equal to zero, tackling the problem of overfitting. After the shrinkage via “glmnet” packages, the optimal A value was acquired [16]. Ultimately, we constructed an ICS score model through the following formula:

$$\text{ICSs score} = \sum_{i=1}^{n} \text{COEF}_i \times \text{NES}_i$$  \hspace{1cm} (1)

where COEF referred to the regression coefficients stemming from univariate Cox regression and NES represented the NES for the corresponding ICS.

2.4. Assessment and Validation of Model. To evaluate the predictive performance of the model, patients in the training cohort were classified into high and low ICS score groups based on the median ICS score. Kaplan-Meier (K-M) survival curves were applied for survival comparison between the high and low ICS score groups. Time-dependent receiver operating characteristic (ROC) curves including survival at 1, 3, and 5 years were established to reflect the sensitivity and specificity of the model. Calibration curves were performed to compare the actual and predicted probability of overall survival (OS) at 1, 3, and 5 years.

2.5. Independent Prognostic Analysis. After initial filtering by univariate Cox analysis, multivariate Cox analysis was conducted to assess the implication of independent prognosis for grade, age, gender, stage, and ICS score variables. Following confirmation of the prognostic value of ICS score, a nomogram integrating clinical traits and the ICS score was constructed to predict the survival probability of each patient. The forecast performance of the nomogram was evaluated by the C-index and calibration curves.

2.6. Immune Infiltration Analysis. We used the ESTIMATE [17] algorithm to calculate the immune infiltration status of immune components. In the ESTIMATE algorithm, we calculated the scores using the “estimateScore” function, which calculated the matrix, immune, and estimated values for each sample based on the gene expression data, so the results were stable when the gene expression data were determined. Moreover, we utilized the CIBERSORT algorithm to estimate the abundance of 22 types of immune cells. In the CIBERSORT algorithm, we set perm = 1000, meaning that a single sample was repeated 1000 times to estimate the P value of immune infiltration so as to obtain stable results. And we run the two algorithms separately more than three times with the same results. Afterwards, we employed the ssGSEA to evaluate the abundance of different immune-associated functions or pathways.

2.7. Mutation Analysis. The somatic variant landscape was visualized by the “maftools” package [18]. Tumor mutation burden (TMB), commonly defined as the total number of nonsynonymous mutations, was proposed as a promising biomarker of immunotherapy [19]. The TMB of each patient between high and low ICS score groups was assessed.

2.8. Immunotherapy Forecast and Drug Sensitivity Analysis. Immunophenoscore (IPS) representing four categories of immunogenicity-determining genes (effector cells, immune suppressor cells, MHC molecules, and immune modulators) was calculated using an unbiased machine learning approach. It has been authenticated that the higher IPS score, the stronger the immunogenicity and the better the response to immunotherapy. The IPS of ccRCC patients were originated from The Cancer Immunome Database (TCIA, https://tcia.at/home) [20].

Genomics of Drug Sensitivity in Cancer (GDSC) (https://www.cancerrxgene.org/) was a publicly available pharmacogenomic database to study the drug sensitivity of cancer cells, which could present a distinct resource for the discovery of new targets for cancer therapy [21]. Half-maximal inhibitory
concentrations (IC50) of common chemotherapeutic agents were estimated by the "pRRophetic" package [22].

2.9. Statistical Analysis. All statistical analysis was implemented using R software (version 4.1.2). Continuous variables between the two groups were compared using the Wilcoxon test. The Chi-square test and Fisher’s exact test were performed to compare categorical variables. Pearson correlation test was used to infer the correlation between the two parameters. All statistical P values were two-sided. Unless otherwise stated, P < 0.05 was considered significant.

3. Results

3.1. Identification of Prognosis-Related Signatures and Construction of ICS Score Model. The detailed demographic and clinical characteristics of ccRCC patients in this study are summarized in Table 1. A total of 515 ccRCC patients from the TCGA-KIRC cohort and 101 ccRCC patients from the E-MTAB-1980 cohort were ultimately enlisted in this study. After univariate Cox regression, 58 ICS were subjected to Lasso-Cox regression for further shrinking. Then, 11 ICS were included and used to build the ICS score model in the training cohort, when the Lasso-Cox regression reached the optimal λ value (0.07290335) (Figures 2(a) and 2(b)). These 11 ICS were

| Variables        | TCGA (n = 515) | E-MTAB-1980 (n = 101) |
|------------------|---------------|-----------------------|
| Status           |               |                       |
| Dead             | 169           | 23                    |
| Alive            | 346           | 78                    |
| Age (years)      |               |                       |
| ≤65              | 340           | 57                    |
| >65              | 175           | 44                    |
| Gender           |               |                       |
| Male             | 336           | 77                    |
| Female           | 179           | 24                    |
| Grade            |               |                       |
| 1                | 13            | 13                    |
| 2                | 224           | 59                    |
| 3                | 205           | 22                    |
| 4                | 73            | 5                     |
| Undetermined     | —             | 2                     |
| Stage            |               |                       |
| I                | 257           | 66                    |
| II               | 54            | 10                    |
| III              | 122           | 11                    |
| IV               | 82            | 14                    |
myeloid dendritic cells MCPcounter, neutrophils MCPcounter, endothelial cells MCPcounter, cytokine receptors, interleukins, IL4 score 21050467, IL8 21978456, interferon receptor, TGF-β family member receptor, Rotterdam ERneg PCA 15721472, and CSR activated 15701700, of which 5 signatures were hazard factors while 6 signatures were protective factors (Figure 2(c)).

3.2. Evaluation and Verification of the ICS Score Model. CcRCC patients were divided into high (n = 251) and low (n = 264) ICS score groups based on the median ICS score. The K-M survival curves revealed significantly favorable OS in the low ICS score group (Figure 3(a)). The distribution curve and survival scatter diagram indicated that patients with a high ICS score had a worse prognosis (Figures 3(b) and 3(c)). Meanwhile, the K-M curves, distribution curve, and survival scatter diagram in the validation cohort were identical to the results of training cohort (Figures 3(d)–3(f)). Analysis of the prognostic prediction efficiencies indicated the model had relatively high area under the curves (AUCs) at 1, 3, and 5 years which were 0.744, 0.713, and 0.742, respectively (Figure 4(a)).
Figure 3: Evaluation of ICS score model. (a) Estimation of the OS in the training cohort. (b) Distribution curve in the training cohort. (c) Survival scatter diagram in the training cohort. (d) Estimation of the OS in the validation cohort. (e) Distribution curve in the validation cohort. (f) Survival scatter diagram in the validation cohort.
The calibration curves delivered a high degree of consistency between predictions and observations in the training cohort (Figure 4(b)). Analogously, the AUCs at 1, 3, and 5 years were 0.796, 0.783, and 0.777 separately and the calibration curves also implied an excellent concordance between predictions and observations in the validation cohort (Figures 4(c) and 4(d)).

3.3. Prognostic Impact of ICS Score Model and Establishment of the Nomogram. Univariate and multivariate Cox regression revealed the ICS score was independently correlated with OS, with a HR of 2.576 (95%CI = 1.801-3.682, \( P < 0.001 \)), along with a HR of stage (1.609, 95%CI = 1.384-1.871, \( P < 0.001 \)), a HR of grade (1.288, 95%CI = 1.026-1.617, \( P = 0.029 \)), and a HR of age (1.025, 95%CI = 1.010-1.040, \( P < 0.001 \)) (Figures 5(a) and 5(b)). To define a quantitatively individual scoring system for each patient, a nomogram that integrated the stage, grade, age, and ICS score was generated (Figure 5(c)). The \( \hat{C} \)-index verified that nomogram manifested a satisfactory prediction in the OS of ccRCC patients (Figure 5(d)) and calibration curves testified a desirable consistency between the predicted and observed values at the odds of 1, 3, and 5 years’ survival (Figure 5(e)).

3.4. Estimation of TME with ICS Score Model. A battery of thorough analysis was conducted to appreciate the immunologic nature between the high and low ICS score groups. Initially, the result of ESTIMATE illustrated that the high ICS score group exhibited a higher ImmuneScore and EstimateScore which entailed a lower TumorPurity (Figure 6(a)). Meanwhile, there was a significant positive correlation between ICS score
Figure 5: Continued.
and ImmuneScore and EstimateScore, as well as a negative correlation between ICS score and TumorPurity (Figures 6(b)–6(d)). Subsequently, the CIBERSORT demonstrated that in the high ICS score group, the antitumor lymphocyte cell subpopulations such as CD8+ T cells, T cell CD4 memory activated, T cell regulatory, and neutrophils were significantly increased. However, the proportions of T cell CD4 memory resting, NK cell resting, monocytes M2, and mast cell resting were significantly decreased (Figure 6(e)). Further, correlation analysis verified the above results (Figure 6(f)). The ssGSEA displayed that the high ICS score group possessed a universally higher infiltration of immune functions apart from type II IFN response (Figure 6(g)). And significant correlations between ICS score and different immune functions were found (Figure 6(h)).

3.5. Comparison of Genomic Alterations between High and Low ICS Score Groups. The mutation scenery between the high and low ICS score groups was analyzed and visualized (Figures 7(a) and 7(b)). In the beginning, the mutation rates were comparable between the high and low ICS score groups (109/134, 81.34% vs. 153/185, 82.70%, \( P = 0.922 \)). Furthermore, the five most frequently mutated genes and the most common mutation type in both high and low ICS score groups were VHL, PBRM1, TTN, SETD2, and BAP1 and missense mutation, accordingly. Subsequently, the mutation rate of BAP1 was significantly rose in the high ICS score group as shown in Table 2 (\( P = 0.004 \)). However, there was no statistical difference of TMB between the high and low ICS score groups (Figure 7(c)). Interestingly, survival analysis noted that patients with an increased level of TMB correlated with a poor OS. And the combination of low mutation and low ICS score group had the most prolonged survival (Figures 7(d) and 7(e)).

3.6. Relationship between ICS Score and Treatment Strategies. To evaluate which group was more applicable for immunotherapy, several immune checkpoint genes [23] and IPS were introduced for investigation. As depicted in Figure 8(a), the expression of immune checkpoint genes was substantially upregulated in exception to programmed cell death 1 ligand 1 (PD-L1) in the high ICS score group. Meanwhile, patients with higher ICS score had significantly higher IPS cytotoxic T lymphocyte-associated antigen-4 (CTLA4)-positive-programmed cell death 1 (PD-1)-positive, IPS-CTLA4-positive-PD-1-negative, IPS-CTLA4-negative-PD-1-positive (Figures 8(b)–8(e)). Additionally, the data of drug susceptibility showed that the high ICS score group patients had a dramatic sensitivity to sunitinib, docetaxel, bortezomib, gefitinib, and dasatinib compared to low ICS score group patients, who exhibited a higher sensitivity to axitinib, pazopanib, and imatinib (Figures 9(a)–9(i)).

4. Discussion

Immune cells in the TME were essential factors affecting the progression, prognosis, and therapy of ccRCC [24]. In this study, we constructed an ICS score model based on 184 ICS. ROC curves and calibration curves corroborated the robust competence of the model to evaluate prognosis. What’s more, higher ICS score was associated with more infiltration of immune cells, higher BAP1 mutation rate and better adaptation to immunotherapy. This highlighted the essential role of the ICS score model in establishing a prognostic prediction system and providing a therapeutic reference for ccRCC patients.

The ICS score embraced 11 ICS. Myeloid dendritic cells generated chemokine ligand 17 that recruited T cells as well as other activated antigen-presenting cells and was an independent prognostic factor for OS in ccRCC patients [25]. Tumor-infiltrating neutrophils were involved in the prognostic deterioration of ccRCC by releasing elastase that broke down cell-cell adhesion and promoted tumor propagation [26]. Interferon receptors, cytokine receptors and interleukins could impair the prognosis of ccRCC through reconfiguring the immune landscape of TME [27, 28]. In addition, TGF-β was also a member of the cytokine family. Reports claimed
**Figure 6: Continued.**
that the deletion of TGF-β receptors triggered the dysregulation of TGF-β signaling which further led to enhanced metastatic of ccRCC [29, 30]. Regarding the role of other ICS in ccRCC, further studies were expected to confirm. In general, these ICS had valuable effects in the occurrence, progression, prognosis, and treatment of ccRCC.

The TME were not simply consisted of the tumor cells but also the stromal cells which can be infiltrated by tumor cells and equipped with tumor-associated effects [31]. Our study observed significant difference in ImmuneScore between high and low ICS score groups, while the StromalScore was not significantly related to ICS score. Therefore, the following analysis principally recounted the immune landscape between high and low ICS score groups. It was unearthed that patients with high ICS score were evidently richer in immune cells and more likely to benefit from immunotherapy, which was inconsistent with the inferiority survival exhibited by high ICS score group patients. A substantial body of studies revealed the immunosuppressive properties of TME in ccRCC patients. Chevrier et al. [32] found that T cells and tumor-associated macrophages

Figure 6: The immune status of ccRCC patients between high and low ICS score groups in the training cohort. (a) ESTIMATE analysis of StromalScore, ImmuneScore, and EstimateScore. (b–d) Correlation of ICSs score and ImmuneScore, EstimateScore, and TumorPurity. (e) CIBERSORT analysis of the relative proportions of immune infiltration for 22 immune cells. (f) CIBERSORT analysis of the correlation between immune infiltration for 22 immune cells and ICS score. (g) ssGSEA of different immune functions. (h) ssGSEA of the correlation between immune functions and ICS score. Levels of statistical significance: *P < 0.05, **P < 0.01, and ***P < 0.001.
(TAMs) were the main immune cell populations in ccRCC. Among them, CD4CD25 regulatory T cell-suppressing T cell immunity was perceived as a principal impediment governing immunotherapy [33]. Meanwhile, high infiltration of M2-like TAMs limited the efficacy of antitumor T cell responses and exhibited high expression of HLA class II as well as
Table 2: Mutation rate of BAP1 in high and low ICS score groups.

| Gene | H-wild | H-mutation | L-wild | L-mutation | P value |
|------|--------|------------|--------|------------|---------|
| BAP1 | 114 (85.07%) | 20 (14.93%) | 176 (95.14%) | 9 (4.86%) | 0.004 |

Figure 8: Prediction of immunotherapy response in the training cohort. (a) Differences of immune checkpoint genes between high and low ICS score groups. (b–e) Differences of IPS between high and low ICS score groups.
Figure 9: Continued.
complement-related genes, which were associated with tumor cells proliferation and resistance to chemotherapy [24, 34–36]. In addition, Zou et al. [37] illustrated upregulation of checkpoint molecules dampened the activity of effector T cells and antigen-presenting cells, impeding an effective antitumor immune response. Together, these contributed to explain why patients in the high ICS score group had a dismal OS despite a high infiltration of immune cells.

In a bid to furnish proper clinical treatment strategies, we would like to figure out whether the ICS score could predict the response to immunotherapy in ccRCC patients. Our study uncovered that the expression of CTLA4 and PD-1 was strikingly elevated in the high ICS score group, which was further validated by IPS, whereas no apparent differences were detected in the PD-L1 expression and TMB between high and low ICS score groups. Although PD-L1 was the most promising biomarker for predicting immunotherapy response for most malignancies, its predictive value continued to be controversial in ccRCC. Motzer et al.’s CHEKIMATE-025 trial showed that irrespective of PD-L1 expression, nivolumab and everolimus improved OS in patients with refractory ccRCC consistently [38]. The inconsistency of detection methods and the variability of the thresholds used to define PD-L1 positivity were probably the most prominent factors. Meanwhile, PD-L1 expression measured by transcriptomic data was not as credible as the intensity and location of PD-L1 expression detected by immunohistochemistry. To understand whether the prognostic effect of ICS score was related to genetic alterations, we compared the disparities of genomic layer between high and low ICS score groups. It was certified that BAP1 mutation evoked augmented expression of C-C chemokine receptor 5 (CCR5) on Tregs and tumor cells. Tumor cells could secrete CCR5 ligands which bonded to CCR5, induced increased PD-L1 expression, and recruited CCR5 Tregs to local TME, thereby enhancing immune escape [39]. Extrapolating from the above results, we speculated that alterations in genes were involved in the prognosis and therapy of ccRCC patients.

There were a few drawbacks for this study. Foremost, it was grounded in public database which deserved further validation in a prospective cohort of patients receiving immunotherapy. Moreover, integrated analysis of multomics in the future will enable to compensate for the current deficiency of exclusive attention to data on transcriptional expression and mutation levels.

![Figure 9: Analysis of drug sensitivity in the training cohort. (a–i) Differences in IC50 of the chemotherapeutic drugs.](image-url)
5. Conclusions

In summary, the ICS score model is very valuable for predicting the prognosis of ccRCC patients and is intimately interrelated with the potency of treatment. This comprehensive model has excellent prediction ability and provides appropriate individualized treatment strategies for ccRCC patients.

Abbreviations

cCRCC: Clear cell renal cell carcinoma
ICS: Immune cell signatures
TME: Tumor microenvironment
NES: Normalized enrichment score
ssGSEA: Single-sample gene set enrichment analysis
Lasso: Least absolute shrinkage and selection operator
TCGA: The Cancer Genome Atlas
TAMs: Tumor-associated macrophages
K-M: Kaplan-Meier
OS: Overall survival
Time-dependent ROC: The time-dependent receiver operator characteristic
AUCs: Area under the curves
TMB: Tumor mutation burden
IPS: Immunophenoscore
TCIA: The Cancer Immunome Database
GDSC: Genomics of Drug Sensitivity in Cancer
IC50: Half-maximal inhibitory concentrations
CTLA-4: Cytotoxic T lymphocyte-associated antigen-4
PD-1: Programmed cell death 1
PD-L1: Programmed cell death 1 ligand 1
CCR5: C-C chemokine receptor 5.

Data Availability

The datasets are available in TCGA database (https://portal.gdc.cancer.gov/) as well as ArrayExpress database (https://www.ebi.ac.uk/arrayexpress/).

Conflicts of Interest

The authors declare that there is no conflict of interest regarding the publication of this paper.

Authors’ Contributions

XZS designed the study. YLN, NNW, MYY, HLZ, AND, and CJY participated in data collection and analysis. XZS drafted this manuscript. YLN and XCJ interpreted the data. YLY, XCJ, and XZS reviewed and revised this manuscript. All authors had approved the final manuscript.

Acknowledgments

The authors thank TCGA and ArrayExpress for sharing the clear cell renal cell carcinoma data.

References

[1] H. Sung, J. Ferlay, R. L. Siegel et al., “Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries,” CA: a Cancer Journal for Clinicians, vol. 71, no. 3, pp. 209–249, 2021.
[2] M. H. Lee, P. Jarvinen, H. Nisen et al., “T and NK cell abundance defines two distinct subgroups of renal cell carcinoma,” Oncoimmunology, vol. 11, no. 1, p. 1993042, 2022.
[3] H. Moch, A. L. Cubilla, A. Humphrey, V. E. Reuter, and T. M. Ulbright, “The 2016 WHO classification of tumours of the urinary system and male genital organs—part A: renal, penile, and testicular tumours,” European Urology, vol. 70, no. 1, pp. 93–105, 2016.
[4] Y. Fu, S. Liu, S. Zeng, and H. Shen, “From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma,” Journal of Experimental & Clinical Cancer Research, vol. 38, no. 1, p. 396, 2019.
[5] X. Zhang, H. Zhao, X. Shi, X. Jia, and Y. Yang, “Identification and validation of an immune-related gene signature predictive of overall survival in colon cancer,” Aging (Albany NY), vol. 12, no. 24, pp. 26095–26120, 2020.
[6] E. Lin, X. Liu, Y. Liu et al., “Roles of the dynamic tumor immune microenvironment in the individualized treatment of advanced clear cell renal cell carcinoma,” Frontiers in Immunology, vol. 12, article 653358, 2021.
[7] D. Bai, H. Feng, J. Yang, A. Yin, A. Qian, and H. Sugiyama, “Landscape of immune cell infiltration in clear cell renal cell carcinoma to aid immunotherapy,” Cancer Science, vol. 112, no. 6, pp. 2126–2139, 2021.
[8] S. Dai, H. Zeng, Z. Liu et al., “Intratumoral CXCL13(+)CD8(+) T cell infiltration determines poor clinical outcomes and immunoevasive contexture in patients with clear cell renal cell carcinoma,” Journal for Immunotherapy of Cancer, vol. 9, no. 2, article e001823, 2021.
[9] E. Jonasch, C. L. Walker, and W. K. Rathmell, “Clear cell renal cell carcinoma ontology and mechanisms of lethality,” Nature Reviews. Nephrology, vol. 17, no. 4, pp. 245–261, 2021.
[10] X. Wu, D. Jiang, H. Liu, X. Lu, D. Lv, and L. Liang, “CD8(+) T cell-based molecular classification with heterogeneous immunogenomic landscapes and clinical significance of clear cell renal cell carcinoma,” Frontiers in Immunology, vol. 12, article 745945, 2021.
[11] W. H. Xu, Y. Xu, J. Wang et al., “Prognostic value and immune infiltration of novel signatures in clear cell renal cell carcinoma microenvironment,” Aging (Albany NY), vol. 11, no. 17, pp. 6999–7020, 2019.
[12] Y. Y. Gu, G. Chen, P. Lin et al., “Development and validation of an immune prognostic classifier for clear cell renal cell carcinoma,” Cancer Biomarkers, vol. 27, no. 2, pp. 265–275, 2020.
[13] S. Sui, X. An, C. Xu et al., “An immune cell infiltration-based immune score model predicts prognosis and chemotherapy effects in breast cancer,” Theranostics, vol. 10, no. 26, pp. 11938–11949, 2020.
[14] S. Wang, Y. Xiong, Q. Zhang et al., “Clinical significance and immunogenomic landscape analyses of the immune cell
signature based prognostic model for patients with breast cancer," Briefings in Bioinformatics, vol. 22, no. 4, 2021.

[15] Y. Liu, J. Hu, D. Liu et al., "Single-cell analysis reveals immune landscape in kidneys of patients with chronic transplant rejection," Theranostics, vol. 10, no. 19, pp. 8851–8862, 2020.

[16] W. Wang and W. Liu, "PClассo: a protein complex-based, group lasso-Cox model for accurate prognosis and risk protein complex discovery," Briefings in Bioinformatics, vol. 22, no. 6, 2021.

[17] K. Yoshihara, M. Shahmoradgoli, E. Martinez et al., "Inferring tumour purity and stromal and immune cell admixture from expression data," Nature Communications, vol. 4, no. 1, p. 2612, 2013.

[18] A. Mayakonda, D. C. Lin, Y. Assenov, C. Plass, and H. P. Koeffler, "Mafools: efficient and comprehensive analysis of somatic variants in cancer," Genome Research, vol. 28, no. 11, pp. 1747–1756, 2018.

[19] L. Liu, X. Bai, J. Wang et al., "Combination of TMB and CNA stratifies prognostic and predictive responses to immunotherapy across metastatic cancer," Clinical Cancer Research, vol. 25, no. 24, pp. 7413–7423, 2019.

[20] C. P. Gui, J. H. Wei, Y. H. Chen et al., "A new thinking: extended application of genomic selection to screen multomics data for development of novel hypoxia-immune biomarkers and target therapy of clear cell renal cell carcinoma," Briefings in Bioinformatics, vol. 22, no. 6, p. bbab173, 2021.

[21] W. Yang, J. Soares, P. Greninger et al., "Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells," Nucleic Acids Research, vol. 41, pp. D955–D961, 2013.

[22] Y. Che, D. Jiang, L. Xu et al., "The clinical prediction value of the ubiquitination model reflecting the immune traits in LUAD," Frontiers in Immunology, vol. 13, article 846402, 2022.

[23] Z. Niu, X. Wang, Y. Xu et al., "Development and validation of a novel survival model for cutaneous melanoma based on necroptosis-related genes," Frontiers in Oncology, vol. 12, article 852803, 2022.

[24] D. A. Braun, K. Street, K. P. Burke et al., "Progressive immune dysfunction with advancing disease stage in renal cell carcinoma," Cancer Cell, vol. 39, no. 5, pp. 632–648.e8, 2021.

[25] Y. Xiong, L. Liu, Y. Xia et al., "Low CCL17 expression associates with unfavorable postoperative prognosis of patients with clear cell renal cell carcinoma," BMC Cancer, vol. 17, no. 1, p. 117, 2017.

[26] B. Tessier-Cloutier, D. D. W. Twa, M. Marzban et al., "The presence of tumour-infiltrating neutrophils is an independent adverse prognostic feature in clear cell renal cell carcinoma," The Journal of Pathology. Clinical Research, vol. 7, no. 4, pp. 385–396, 2021.

[27] E. Duong, T. B. Fessenden, E. Lutz et al., "Type I interferon activates MHC class I-dressed CD11b+ conventional dendritic cells to promote protective anti-tumor CD8+ T cell immunity," Immunity, vol. 55, no. 2, pp. 308–323.e9, 2022.

[28] J. Nishida, Y. Momoi, K. Miyakuni et al., "Epigenetic remodeling shapes inflammatory renal cancer and neutrophil-dependent metastasis," Nature Cell Biology, vol. 22, no. 4, pp. 465–475, 2020.

[29] S. Mirzaei, M. D. A. Paskeh, Y. Saghari et al., "Transforming growth factor-beta (TGF-β) in prostate cancer: a dual function mediator?," International Journal of Biological Macromolecules, vol. 206, pp. 435–452, 2022.

[30] J. Nishida, K. Miyazono, and S. Ehata, "Decreased TGFBR3/beta2glycan expression enhances the metastatic abilities of renal cell carcinoma cells through TGF-β-dependent and -independent mechanisms," Oncogene, vol. 37, no. 16, pp. 2197–2212, 2018.

[31] S. Bose, P. Saha, B. Chatterjee, and A. K. Srivastava, "Chemo-kines driven ovarian cancer progression, metastasis and chemoresistance: potential pharmacological targets for cancer therapy," Seminars in Cancer Biology, vol. 84, 2022.

[32] S. Chevrier, J. H. Levine, V. R. T. Zanotelli et al., "An immune atlas of clear cell renal cell carcinoma," Cell, vol. 169, no. 4, pp. 736–749.e18, 2017.

[33] W. Zou, "Regulatory T cells, tumour immunity and immunotherapy," Nature Reviews. Immunology, vol. 6, no. 4, pp. 295–307, 2006.

[34] Q. Wang, J. Zhang, H. Tu et al., "Soluble immune checkpoint-related proteins as predictors of tumor recurrence, survival, and T cell phenotypes in clear cell renal cell carcinoma patients," Journal for Immunotherapy of Cancer, vol. 7, no. 1, p. 334, 2019.

[35] M. Y. Koh, N. Sayegh, and N. Agarwal, "Seeing the forest for the trees—single-cell atlases link CD8+ T cells and macrophages to disease progression and treatment response in kidney cancer," Cancer Cell, vol. 39, no. 5, pp. 594–596, 2021.

[36] C. Krishna, R. G. DiNatale, F. Kuo et al., "Single-cell sequencing links multiregional immune landscapes and tissue-resident T cells in ccRCC to tumor topology and therapy efficacy," Cancer Cell, vol. 39, no. 5, pp. 662–677.e6, 2021.

[37] C. M. Diaz-Montero, B. I. Rini, and J. H. Finke, "The immunology of renal cell carcinoma," Nature Reviews. Nephrology, vol. 16, no. 12, pp. 721–735, 2020.

[38] R. J. Motzer, B. Escudier, D. McDermott et al., "Nivolumab versus everolimus in advanced renal-cell carcinoma," The New England Journal of Medicine, vol. 373, no. 19, pp. 1803–1813, 2015.

[39] Q. Zhou, Y. Qi, Z. Wang et al., "CCR5 blockade inflames anti-tumor immunity in BAP1-mutant clear cell renal cell carcinoma," Journal for Immunotherapy of Cancer, vol. 8, no. 1, p. e00228, 2020.